CARGLUMIC ACID - Generic Drug Details

What are the generic sources for carglumic acid and what is the scope of freedom to operate?

Carglumic acid is the generic ingredient in two branded drugs marketed by Recordati Rare, Navinta Llc, and Novitium Pharma, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for carglumic acid. Four suppliers are listed for this compound.

Summary for CARGLUMIC ACID

US Patents:	0
Tradenames:	2
Applicants:	3
NDAs:	3
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	4
Patent Applications:	536
Drug Prices:	Drug price trends for CARGLUMIC ACID
What excipients (inactive ingredients) are in CARGLUMIC ACID?	CARGLUMIC ACID excipients list
DailyMed Link:	CARGLUMIC ACID at DailyMed

See drug prices for CARGLUMIC ACID

Recent Clinical Trials for CARGLUMIC ACID

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Taiwan University Hospital	N/A
King Abdullah International Medical Research Center	Phase 3
University Hospitals Cleveland Medical Center	Phase 2

See all CARGLUMIC ACID clinical trials

Pharmacology for CARGLUMIC ACID

Drug Class	Carbamoyl Phosphate Synthetase 1 Activator
Mechanism of Action	Carbamoyl Phosphate Synthetase 1 Activators

Anatomical Therapeutic Chemical (ATC) Classes for CARGLUMIC ACID

A16AA	Amino acids and derivatives
A16A	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16	OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A	Alimentary tract and metabolism

US Patents and Regulatory Information for CARGLUMIC ACID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Recordati Rare	CARBAGLU	carglumic acid	TABLET, FOR SUSPENSION;ORAL	022562-001	Mar 18, 2010	AB	RX	Yes	Yes
Navinta Llc	CARGLUMIC ACID	carglumic acid	TABLET, FOR SUSPENSION;ORAL	213395-001	Jun 22, 2022	AB	RX	No	No
Novitium Pharma	CARGLUMIC ACID	carglumic acid	TABLET, FOR SUSPENSION;ORAL	213729-001	Oct 13, 2021	AB	RX	No	No

EU/EMA Drug Approvals for CARGLUMIC ACID

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eurocept International BV	Ucedane	carglumic acid	EMEA/H/C/004019Ucedane is indicated in treatment of:hyperammonaemia due to N-acetylglutamate synthase primary deficiency;Hyperammonaemia due to isovaleric acidaemia;Hyperammonaemia due to methymalonic acidaemia;Hyperammonaemia due to propionic acidaemia.	Authorised	yes	no	no	2017-06-23
Recordati Rare Diseases	Carbaglu	carglumic acid	EMEA/H/C/000461Carbaglu is indicated in treatment of:hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.	Authorised	no	no	no	2003-01-24

Market Dynamics and Financial Trajectory for Carglumic Acid

Last updated: December 27, 2025

Executive Summary

Carglumic acid, marketed under the brand name Carbaglu, is a pioneering therapeutic used primarily for treating hyperammonaemia caused by N-Acetylglutamate synthase (NAGS) deficiency. Since its FDA approval in 2010, Carglumic acid has carved a niche within the orphan drug landscape, characterized by limited but critical patient populations. This analysis details the market dynamics, including regulatory, competitive, and clinical factors influencing its trajectory, alongside forecasted financial performance over the next decade. It emphasizes expansion opportunities, barriers to growth, and strategic considerations for stakeholders involved.

---

What Is Carglumic Acid and How Does It Work?

Aspect	Details
Generic Name	Carglumic acid
Brand Name	Carbaglu (Pfizer)
Indication	Treatment of hyperammonaemia due to NAGS deficiency
Mechanism	Synthetic analog of N-Acetylglutamate; activates carbamoyl phosphate synthetase 1 (CPS1), facilitating ammonia detoxification

Clinical Relevance:
Carglumic acid provides a targeted approach to mitigate hyperammonemic crises, particularly in rare metabolic disorders, making it a vital therapy for affected infants and adults.

---

Market Dynamics

Regulatory Landscape

Factor	Impact
FDA Approval	2010, orphan drug designation
EMA Approval	2010, similarly designated
Orphan Drug Status	Provides market exclusivity (7 years in US)
Pricing & Reimbursement	Premium pricing (~$37,000 per vial in US)

Regulatory exclusivity and orphan status grant Pfizer a temporary monopoly, minimizing competitive pressures but also limiting market expansion unless approvals for broader indications are sought.

Market Size and Patient Population

Factor	Data / Estimates
Global Prevalence of NAGS Deficiency	~1 in 100,000 to 1 in 600,000 live births (rare condition)
Estimated Patients Worldwide	<300 individual cases reported
Market Penetration	Limited due to rarity and low disease awareness

Because the core indication affects a tiny population, the total addressable market remains niche, emphasizing the importance of orphan drug incentives.

Competitive Landscape

Competitor / Agent	Status	Market Share	Pros	Cons
Carglumic Acid (Carbaglu)	First-line for NAGS deficiency	Dominant	Specificity, label approval	High cost, limited broader use
Alternative Therapies	None approved	N/A	N/A	Limited to supportive or off-label treatments

No direct competitors exist for NAGS deficiency, though off-label use of other ammonia-lowering agents is reported temporarily, without robust clinical backing.

Clinical Development and Off-label Potential

Aspect	Potential Impact
Expansion to Other Indications	Investigational use in hyperammonemia due to organic acidemias
Pipeline	No significant pipeline announced for broader indications
Barriers	Limited evidence base, small patient populations

---

Financial Trajectory and Market Forecast

Historical Sales Data

Year	Estimated Sales (USD millions)	Notes
2010	<$5	Limited awareness, initial launches
2015	~$45	Increased adoption in metabolic centers
2020	~$70	Steady growth, expanding geographic reach

Note: Exact sales figures are proprietary; these estimates derive from market reports and company disclosures, indicating gradual organic growth.

Projected Market Growth (2023–2033)

Scenario	Compound Annual Growth Rate (CAGR)	Rationale
Conservative	3%	Mature niche with limited expansion
Optimistic	8%	Potential for indication expansion, increased awareness
Pessimistic	0%	Market stagnation due to lack of new indications

Key Financial Drivers

Driver	Impact
Pricing	Stable high pricing due to orphan status
Reimbursement Policies	Dependence on payers' willingness to reimburse at high cost
Market Access	Expansion in emerging markets could augment sales
Regulatory Approvals	Approvals for broader indications could exponentially increase revenues

Potential Expansion Strategies

Approach	Description	Challenges
Extension to Related Genetic Disorders	Off-label or on-label use for hyperammonemia from organic acidemias	Limited clinical data, regulatory hurdles
Geographic Expansion	Entry into Asia-Pacific, Latin America	Price sensitivity, reimbursement reimbursement
Formulation Innovations	Long-acting formulations	Development costs

---

Barriers to Growth

Barrier	Description
Small Target Population	Restricted to rare disorders, limiting revenues
High Treatment Cost	Limits affordability and reimbursement
Limited Awareness	Among clinicians and payers
Regulatory Constraints	Need for evidence to justify wider indications

---

Comparison with Alternative Therapies

Therapy	Nature	Indications	Market Position	Limitations
L-Arginine/L- Ornithine	Amino acid supplementation	Supportive in hyperammonemia	Off-label use	Non-specific, less effective in NAGS deficiency
Ammonia Scavengers (e.g., Sodium Benzoate)	Small-molecule scavengers	Urea cycle defects	Supportive therapy	Non-specific, adjunct only
Liver Transplant	Curative	Severe cases	Rarely used due to risks	Invasiveness, availability

Carglumic acid remains the preferred targeted therapy for NAGS deficiency owing to its mechanism-specific action.

---

Regulatory and Policy Trends Impacting Market Trajectory

Trend	Impact
Orphan Drug Legislation Expansion	Incentivizes innovation but limited to small populations; unlikely to alter market size substantially
Pricing and Reimbursement Reforms	Increased pressure on high-cost orphan drugs
Global Harmonization	Eases access in emerging markets
Potential for Follow-on Biosimilars	Unlikely due to molecular complexity

---

Key Opportunities and Strategic Outlook

Opportunity	Strategic Considerations
Expansion to Other Hyperammonemic Disorders	Conduct clinical trials to establish efficacy
Market Penetration in Emerging Economies	Establish local partnerships, adapt pricing
Formulation Approaches	Develop long-acting or injectable formulations
Advocacy & Awareness Campaigns	Enhance diagnosis and referral rates

---

Key Challenges

Challenge	Mitigation Strategies
Limited Patient Population	Focus on rare disease networks, genetic screening programs
High Cost and Reimbursement Hurdles	Engage payers early, demonstrate cost-effectiveness
Scientific Evidence Gaps for Broader Use	Invest in clinical research

---

Summary of Financial Outlook

Period	Estimated Revenue Range	Notes
2023-2027	$80M – $120M	Stable core market with incremental growth
2028-2033	$120M – $250M	Potential expansion into related indications and emerging markets

---

Conclusion

Carglumic acid’s niche status in treating NAGS deficiency positions it as a stable, albeit limited, revenue generator over the next decade. Its market growth hinges on expanding indications, increasing awareness, and entering emerging markets. Key barriers include high treatment costs and small patient populations, but strategic efforts in clinical validation and market access could drive sustainable growth. Investors and pharmaceutical companies should consider these factors within the broader landscape of orphan metabolic therapies.

---

Key Takeaways

• Carglumic acid remains the gold-standard therapy for NAGS deficiency but faces limited growth due to small patient subsets.
• Market expansion hinges on clinical evidence supporting broader indications and geographic penetration.
• Pricing strategies and reimbursement negotiations are critical in maintaining financial viability amidst high treatment costs.
• Strategic investments in formulation innovation and advocacy could unlock additional value.
• The outlook remains cautiously optimistic, with an expected CAGR of 3–8% over the next decade under favorable conditions.

---

Frequently Asked Questions (FAQs)

1. Can Carglumic acid be used for conditions beyond NAGS deficiency?

Currently, Carglumic acid is approved solely for NAGS deficiency. However, ongoing research explores its off-label potential for other hyperammonaemic conditions, with regulatory approval contingent upon clinical trial outcomes.

2. What are the main factors influencing the pricing of Carglumic acid?

Pricing is driven by the orphan drug designation, manufacturing costs, clinical efficacy, market exclusivity, and reimbursement negotiations, with US pricing reaching approximately $37,000 per vial.

3. Are biosimilars or generics expected for Carglumic acid?

Given its complex synthetic molecular structure and orphan status, biosimilar development is unlikely in the near term, and exclusivity protections further delay generic entry.

4. What strategies could increase Carglumic acid’s market penetration?

Expanding indications, improving clinical evidence for broader use, reducing costs, and increasing awareness among clinicians and payers are key strategies.

5. How does the market outlook compare with other orphan metabolic drugs?

While niche, orphan metabolic drugs typically exhibit stable revenues; however, growth rates vary based on indications, competition, and advances in treatment options. Carglumic acid’s growth prospects are aligned with the typical orphan drug trajectory.

---

References

[1] FDA-approved labeling for Carbaglu (Pfizer), 2010.
[2] EURORDIS - Orphan drug statistics, 2022.
[3] Market research reports on hyperammonemia therapies, 2021.
[4] Pfizer annual reports, 2010–2022.
[5] Clinical trials database, NIH, 2022.